As this happened, Citigroup upgraded its Summit Therapeutics Inc [SMMT] rating to a Buy from a a Neutral in a research note published on March 26, 2025; the price target was increased to $35 from $23. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in late March with a ‘”an Overweight”‘ rating. Evercore ISI began covering SMMT with “an Outperform” recommendation on March 12, 2025. Goldman started covering the stock on February 28, 2025. It rated SMMT as “a Buy”.
Price Performance Review of SMMT
On Tuesday, Summit Therapeutics Inc [NASDAQ:SMMT] saw its stock fall -5.78% to $24.62. Over the last five days, the stock has gained 47.96%. Summit Therapeutics Inc shares have risen nearly 37.97% since the year began. Nevertheless, the stocks have risen 571.76% over the past one year. While a 52-week high of $33.89 was reached on 04/15/25, a 52-week low of $2.10 was recorded on 04/07/25. SMA at 50 days reached $20.00, while 200 days put it at $17.84.
Levels Of Support And Resistance For SMMT Stock
The 24-hour chart illustrates a support level at 23.16, which if violated will result in even more drops to 21.69. On the upside, there is a resistance level at 26.16. A further resistance level may holdings at 27.69. The Relative Strength Index (RSI) on the 14-day chart is 63.27, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 4.52, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 15.07%. Stochastics %K at 94.36% indicates the stock is a selling.
How much short interest is there in Summit Therapeutics Inc?
A steep rise in short interest was recorded in Summit Therapeutics Inc stocks on 2025-03-31, growing by 2.13 million shares to a total of 23.77 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 21.63 million shares. There was a rise of 8.98%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 08, 2025 when Truist began covering the stock and recommended ‘”a Buy”‘ rating along with a $35 price target.
